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390Objective: The angiotensin-converting enzyme (ACE) is highly expressed in the aneurysmal vascular wall, in
both animal models and human disease. Genetic variations in ACE could be crucial in determining the risk of
thoracic aortic aneurysm (TAA). The aim of the present study was to examine the role of ACE insertion/deletion
polymorphism on the risk of TAA in patients with bicuspid aortic valves or tricuspid aortic valves.
Methods:We enrolled 216 patients (158 men; age, 58.9 14.9 years) with TAA, associated with bicuspid aortic
valves (n ¼ 105) and tricuspid aortic valves (n ¼ 111) compared with 312 patients (252 men; age, 54.6  11.0
years) with angiographically proven coronary artery disease and 300 healthy controls (91 men; age, 40.4 10.5
years).
Results: The genotype distribution of ACE insertion/deletion was significantly different between the patients
with TAA compared with both the control group (P ¼ .0005) and the coronary artery disease group
(P ¼ .03). The genotypes were not different between the control group and the coronary artery disease group
(P ¼ .3). Compared with the controls, both the bicuspid aortic valve patients (P ¼ .0008) and tricuspid aortic
valve patients (P<.0001) had a greater frequency of allele D. The aortic diameters were significantly different
among the three genotypes (48.3  6.6, 45.3  8.9, 39.9  8.7 for the DD, DI, and II genotypes, respectively;
P ¼ .0002). A synergistic effect between the ACE D allele and hypertension was found for both an increased
aortic diameter (P¼ .003) and the risk of TAA (P<.001). On multivariate logistic regression analysis, D allele
(odds ratio, 3.0; 95% confidence interval, 1.1–8.1; P ¼ .03) was a significant predictor of TAA.
Conclusions: ACE insertion/deletion polymorphism represents a genetic biomarker for TAA. These findings
could have a significant effect on both the early detection and effective pharmacologic treatment of aortic dis-
ease. (J Thorac Cardiovasc Surg 2012;144:390-5)Thoracic aortic aneurysm (TAA), involving the ascending
aorta, is a highly fatal cardiovascular disorder.1 Aneurysms
of the ascending thoracic aorta most often result from cystic
medial degeneration, associated with tricuspid aortic valves
(TAVs) or congenital bicuspid aortic valves (BAVs). Clini-
cal studies have also shown that ascending aortic dilatation
occurs more frequently and at a younger age in patients with
BAVs than it does in patients with normal TAVs.1-3
During the past decade, several studies have investigated
the genetic basis of TAA, focusing on its relation to sys-
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The Journal of Thoracic and Cardiovascular Surgand Ehlers–Danlos syndrome, and/or familial cases with an
autosomal dominant pattern.1-4
Several mutations and loci have been identified, and ad-
ditional studies to identify the specific genes involved in the
pathogenesis of familial but nonsyndromic TAAs are in
progress.4,5
Common genetic variants could also play a role in the oc-
currence and progression of TAA, but they are largely
unknown.6
The identification of the biochemical and genetic bio-
markers is a fundamental strategy to monitor the develop-
ment and progression of the aortic diameter and to tailor
the medical and surgical approaches to this serious
condition.2,6
The renin-angiotensin system (RAS) has been suggested
to be crucial in the development of both abdominal aortic
aneurysms (AAAs) and TAAs.7 Genetic variability in the
RAS might, thus, play a role in the development of TAAs,
allowing individualized treatment of patients at risk of acute
aortic syndromes. Recent studies have shown that the
angiotensin-converting enzyme (ACE) insertion/deletion
(I/D) polymorphism represents a marker of increased sus-
ceptibility to AAAs.8-10 The aim of the present study wasery c August 2012
Abbreviations and Acronyms
AAA ¼ abdominal aortic aneurysm
ACE ¼ angiotensin-converting enzyme
BAV ¼ bicuspid aortic valve
CAD ¼ coronary artery disease
CI ¼ confidence interval
I/D ¼ insertion/deletion
OR ¼ odds ratio
RAS ¼ renin-angiotensin system
TAA ¼ thoracic aortic aneurysm
TAV ¼ tricuspid aortic valve
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development of TAAs in patients with BAVs and TAVs.
METHODS
Subjects
From January 2008 to March 2010, we enrolled 216 patients (158 men;
age 58.9 14.9 years) whowere referred to our cardiac surgery department
for TAA, associated with BAVs (n ¼ 105) or TAVs (n ¼ 111).
Of these 216 patients, 90 had limited dilatation (maximal aortic diame-
ter<45 mm), and 126 had a large aneurysm (aortic diameter45 mm), es-
timated using computed tomography scans and/or angiography. Of the
patients with an aneurysm (aortic diameter 45 mm) 53 (42%) and 73
(58%) had BAVs or TAVs, respectively. A total of 167 patients underwent
elective surgery for replacement of the ascending aorta and/or aortic valve
replacement.
We also included a group of 312 patients (252 men; age, 54.6  11.0
years) with angiographically proven coronary artery disease (CAD).
A group of 300 healthy subjects (91 men; age, 40.4  10.5 years), who
were members of the medical and technical staff of our institution, and who
were negative for any clinical evidence of cardiovascular disease, was used
as the control group.
A complete history, including cardiovascular risk factors, such as hyper-
tension, diabetes, and dyslipidemia, was collected from all patients. The
following definitions were used for the risk factors: hypertension, blood
pressure 140/90 mm Hg (confirmed by measurements on several occa-
sions), or antihypertensive therapy; and dyslipidemia, low-density lipopro-
tein 130 mg/dL or more, high-density lipoprotein less than 35 mg/dL,
triglycerides 200 mg/dL or more, or the use of lipid-lowering medications.
Current smokers were defined as patients with moderate or heavy use of
cigarettes (3 cigarettes/day) at entry into the study. Former smokers
were defined as the participants who had been smoking regularly, at least
3 cigarettes/day and who had quit smoking for at least 6 months at enroll-
ment. Nonsmokers were defined as patients who had never smoked before
admission. The smoker group combined the past and current smokers. Ac-
cordingly, each risk factor was coded as either present or absent. Thosewith
Marfan syndrome and traumatic aneurysmswere excluded from the present
study.
The aortic diameters were measured by imaging only in the patients re-
ferred to our cardiac surgery department for TAA. All participants provided
informed consent, and the local ethical research committee approved the
study.
Detection of ACE Polymorphism
Genotyping analysis was performed by our laboratory staff, who were
unaware of the clinical data. Genomic DNAwas extracted from the periph-
eral blood leukocytes.The Journal of Thoracic and CaThe ACE I/D polymorphism was genotyped as previously described in
published protocols.8-10 In brief, polymerase chain reaction was performed
with 10 pmol of each primer: sense oligo 50-CTG GAG ACC ACT CCC
ATC CTT TCT-30 and anti-sense oligo 50-GAT GTG GCC ATC ACA
TTC GTC AGAT-30 in a final volume of 50 mL, containing 3 mM of mag-
nesium chloride, 50 mM of potassium chloride, 10 mM of Tris (hydroxy-
methyl) aminomethane hydrochloride (pH 8.4), 0.1 mg/mL of gelatin, 0.5
mM of deoxynucleotidetriphosphate, and 1 unit of Taq polymerase. The
DNAwas amplified for 30 cycles with denaturation at 94C for 1 minute,
annealing at 58C for 1 minute, and extension at 72C for 2 minutes. The
ACE I/D polymorphism consists of the presence/absence of a 287-bp DNA
fragment corresponding to an Ala repetitive sequence in the intron 16 of the
ACE gene, determining the insertion (I) and deletion (D) allele.
The polymerase chain reaction products corresponding to the insertion
(480 bp) or deletion (193 bp) allele were analyzed on 1.5% agarose gel
stained with ethidium bromide.
Statistical Analysis
Statistical analyses of the data were performed with the StatView statis-
tical package, version 5.0.1 (Abacus Concepts, Berkeley, Calif).
Data are expressed as the mean  standard deviation. Differences in
noncontinuous variables were tested by chi-square analysis. Differences
between the mean of the 2 continuous variables were evaluated using Stu-
dent t test. The data for three different groups were analyzed using analysis
of variance, and significant differences among pairs of the mean values
were tested using Scheffe’s test.
The Scheffe test was chosen for multiple comparisons, because it is very
robust for the violations of the assumptions that are typically associated
with multiple comparisons procedures. Interaction terms were also intro-
duced in the model to examine the interaction of the genotypes with hyper-
tension. We calculated the odds ratios (ORs) and 95% confidence intervals
(CIs) for the association of the ACE I/D polymorphismwith the presence of
TAA using unconditional logistic regression analysis. Multivariate logistic
regression analysis was used to estimate the ORs after adjustment for the
other vascular risk factors. Power calculations showed that the study sam-
ple was able to detect an association between ACE I/D polymorphism and
TAAwith ORs of 2.5 to 3.0, based on a deletion allele frequency of 0.6.6RESULTS
The demographic and clinical characteristics of the study
population are reported in Table 1. Age (P<.0001) and the
proportion of men (P<.0001) were significantly greater in
the TAA group than in the control group. The prevalence of
smoking (P¼ .04), hypertension (P<.0001), and dyslipide-
mia (P<.0001) was also significantly greater in the TAA
and CAD patients than in the control subjects (Table 1).
The prevalence of atherogenic risk factors (including age,
gender, hypertension, diabetes, cigarette smoking, dyslipi-
demia) was also significantly greater in the CAD group
than in the control group (Table 1). Age (P ¼ .0002) and
the incidence of hypertension (P ¼ .04) were significantly
greater in the TAA group than in the CAD group (Table 1).
The ACE I/D genotype distribution of the study popula-
tions is summarized in Table 2. The genotype distribution of
ACE I/D was significantly different between the patients
with TAA and both the control (P ¼ .0005) and the CAD
(P ¼ .03) group. No significant difference was found in
the genotype frequency between the control group and the
CAD group (P ¼ .3).rdiovascular Surgery c Volume 144, Number 2 391
TABLE 1. Clinical and demographic characteristics of study
population
Characteristic
TAA group
(n ¼ 216)
CAD group
(n ¼ 312)
Control group
(n ¼ 300)
Mean age 58.9  14.9*,y 54.6  11.0* 40.4  10.5
Male gender 158 (73.1)*,z 252 (80.8)* 91 (30.3)
Smoking habit 89 (41.2)x,k 203 (65.1)* 95 (31.7)
Diabetes mellitus 14 (6.5) 31 (9.9)x 10 (3.3)
Dyslipidemia 63 (29.2)*,k 230 (73.7)* 27 (9.0)
Hypertension 112 (51.8)*,z 134 (42.9)* 29 (9.7)
Date presented as mean  standard deviation or numbers, with percentages in pa-
rentheses. TAA, Thoracic aortic aneurysm; CAD, coronary artery disease.
*P<.0001 vs controls. yP<.01 vs CAD. zP<.05 vs CAD. xP<.05 vs controls.
kP<.0001 vs CAD.
TABLE 3. Association betweenACE I/D polymorphism and ascending
aortic aneurysm
Model OR (95% CI) P value
Additive (DD vs DI vs II) 2.7 (1.5–5.2) .001
Dominant (DD and ID vs II) 2.8 (1.6–5.0) .0004
Recessive (DD versus ID and II) 1.2 (0.8–1.8) .3
OR, Odds ratio; CI, confidence interval; other abbreviations as in Table 2.
Congenital Heart Disease Foffa et al
C
H
DThe ACE deletion allele was significantly more frequent
in both BAV (64%, P ¼ .0008) and TAV (64%, P<.0001)
patients than in the control group (57%).
When patients were stratified by the presence of a large
aneurysm (aortic diameter 45 mm), the ACE deletion al-
lele was still significantly more frequent in both BAV (71%,
P¼ .03) and TAV (71%, P¼ .001) patients than in the con-
trol group (57%).
Univariate logistic regression analysis demonstrated that
ACE I/D polymorphism was related to nearly a threefold in-
creased TAA risk in both the dominant and the additive ge-
netic models (Table 3).
The aortic diameter was also significantly different
among the three genotypes (48.3  6.6, 45.3  8.9, and
39.9  8.7 for the DD, DI, and II genotypes, respectively;
P ¼ .0002). Patients with the DD (P ¼ .0003) and ID
(P ¼ .003) genotypes had significantly greater aortic diam-
eters than patients with the II genotype. Also, a significant
difference (P¼ .04) was found in the DD versus ID patients
(Figure 1).
The aortic diameters were also significantly different
among the three genotypes for both BAV and TAV patients
(Figure 1). Furthermore, we found a synergistic effect be-
tween the ACE deletion allele and hypertension
(Figure 2) for both increased aortic diameter (P ¼ .03)
and the risk of TAA (P¼ .001). On multivariate logistic re-
gression analysis, hypertension (OR, 1.7; 95% CI, 1.0–6.1;
P ¼ .04), age (OR, 1.0; 95% CI, 1.0–1.1; P ¼ .03), maleTABLE 2. Genotype distribution of ACE I/D polymorphism
Genotype
Allele
frequency
Control
group
CAD
group
TAA
group*,y
ACE II 65 (21.7) 54 (17.3) 20 (9.3)
ACE ID 126 (42.0) 144 (46.2) 115 (53.2)
ACE DD 109 (36.3) 114 (36.5) 81 (37.5)
ACE D 0.57% 0.60% 0.64%z,x
Data presented as numbers, with percentages in parentheses, unless otherwise noted.
ACE, Angiotensin-converting enzyme; I/D, insertion/deletion; other abbreviations as
in Table 1. *P<.01 vs controls. yP<.05 vs CAD. zP<.0001 vs controls. xP<.01 vs
controls.
392 The Journal of Thoracic and Cardiovascular Surggender (OR, 2.6; 95% CI, 1.2–5.6; P ¼ .02), and deletion
allele (OR, 3.0; 95% CI, 1.1–8.1; P ¼ .03) were significant
determinants of TAA.DISCUSSION
The present study showed that the ACE deletion allele is
significantly associated with both a large aortic diameter
and an increased risk of TAA. In addition, we observed
a synergic effect between the ACE I/D polymorphism and
hypertension on the risk of TAA.RAS, ACE I/D Polymorphism, andAortic Aneurysms
Increasing data have consistently reported that inappro-
priate activity of the RAS is an underlying cause of aortic
aneurysmal disease.7 For instance, infusion of angiotensin
II in apolipoprotein E-deficient mice induced large aneu-
rysm formation independently of blood pressure
changes.11,12 In addition, administration of losartan, the
angiotensin II type 1 antagonist, completely attenuated
the aortic pathology in a Marfan mouse model.13
Angiotensin II is known to play a crucial role in the re-
modeling of vascular tissues by activation of growth factors
and cytokines, in addition to the regulation of blood
pressure.7,14
Angiotensin II also increases transforming growth factor-
b transcription and synthesis and induces an increase in ma-
trix metalloproteinases activity, leading to inflammation,
extracellular matrix degradation, and apoptosis.7,15-17
ACE plays a key role in the RAS, because it generates the
active octapeptide angiotensin II from the decapeptide
angiotension I.
Importantly, ACE is highly expressed in the aneurysmal
vascular wall, both in human disease and animal
models.18,19 In aneurysmal aortic specimens obtained
during operative repair of patients, ACE activity was
increased sixfold.19
It is well-known that patients with the DD genotype have
high ACE levels in their plasma and cardiac tissue.20,21
Therefore, the very common ACE I/D polymorphism
could contribute to the risk of aortic aneurysmal diseases.
Recent studies have documented that ACE I/D
polymorphism represents a susceptibility factor for
AAA.8-10 Moreover, a large study of three geographically
distinct, but ethnically similar, case-control cohorts con-
firmed a role for the ACE gene in modulating theery c August 2012
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FIGURE 1. Aortic diameters according to angiotensin-converting enzyme insertion/deletion polymorphism for (A) all patients, (B) bicuspid aortic valve
patients, and (C) tricuspid aortic valve patients.
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1166A>C polymorphism represented a risk factor for
AAA.22
Clinical and Pharmacogenetics Implications
Our findings have relevant implications for the care of
patients and research both. Current American College of
Cardiology/American Heart Association guidelines recom-
mend replacement of the ascending aorta in select patients
(eg, patients with Marfan syndrome, BAV patients requiring
concomitant aortic valve replacement) with a ascending
aortic diameter greater than 4.5 cm.23 These recommenda-
tions, however, were based almost exclusively on ‘‘expert
opinion,’’ and improved clinical predictors are needed to
identify those at risk of acute aortic dissection and to deter-
mine the aortic diameter that justifies the risk of surgical re-
pair of a TAA.24,25 Clinical studies of familial TAA have
provided the evidence that the timing of surgical repairHypertension / ACE D
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The Journal of Thoracic and Cacan be dictated by the underlying mutated gene causing
the disease.24 In the clinical setting, the identification of
common genetic risk factors for TAA could also facilitate
risk stratification to prevent or attenuate the disease.2,6
The combination of genetic tests and clinical routine
examinations could contribute to the personalized
prevention of this condition. A better understanding of the
genetic component predisposing to TAA remains the
challenge for the future for selecting the optimal medical
regimen for each patient. Currently, the medical therapies
for aortic disease entail aggressive management of
cardiovascular risk, especially hypertension, to control the
growth of the aortic aneurysm and reduce its risk of
dissection or rupture. Our findings suggest that RAS
inhibition could be considered as first-line therapy in pre-
venting aortic aneurysmal disease.
Furthermore, data from animal models have suggested
that ACE inhibitors slow the progressive course of aorticO
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ture than other antihypertensive agents.13,26-28
Avery recent experimental study has shown that the AT1
receptor blocker, losartan, which uniquely blocks trans-
forming growth factor-b activity, allowing intact AT2 sig-
naling, abrogated aneurysm progression in the Marfan
mice. In contrast, the ACE inhibitor, enalapril, which limits
signaling through both receptors, was less effective. In the
mouse studies, losartan reduced ERK1/2 phosphorylation
through a combination of inhibiting AT1 receptor-
mediated ERK activation and by shunting angiotensin II
signaling through the AT2 receptor. This lends further sup-
port to the idea that an AT1 receptor blocker might be supe-
rior to ACE inhibitors for clinical treatment.29
ACE inhibitors have recently been associated with a re-
duced risk of rupture in patients with AAAs.30 Limited
data, however, are currently available regarding the poten-
tial benefit of ACE inhibitors or angiotensin II receptor
blockers for ascending aortic aneurysms.
Recent studies have demonstrated that ACE inhibitors
significantly reduced both the aortic stiffness index and aor-
tic root growth in patients with Marfan syndrome.31,32 The
angiotensin II receptor blocker losartan has also been shown
to reduce the rate of aortic dilatation in a small pediatric
cohort of patients with Marfan syndrome.33
However, no evidence has suggested whether angiotensin
II receptor blockers are preferable to b-blockers for aortic
disease.
Currently, ongoing randomized clinical trials are com-
paring the efficacy of standard treatment with b-adrenocep-
tor blockade, with the AT1 receptor antagonism using
losartan, in patients with Marfan syndrome.34-36 The
results of these trials may help to better define which of
these therapies is of greater benefit for the long-term treat-
ment of these patients and to better clarify the role of the
RAS in ascending aortic aneurysm.
However, genetic variants in the RAS genes could also
modify the efficacy of the therapies. Therefore, it would
be important to perform large pharmacogenetic studies to
evaluate whether gene–drug interactions vary the risk of
TAA and to identify specific populations that would benefit
from specific treatments.
Study Limitations
Some important limitations must be considered when in-
terpreting the results of the present study. First, the patho-
genesis of aortic aneurysmal disease is undoubtedly
complex, involving many genes acting in an additive or in-
teractive manner, together with environmental factors. The
RAS represents a perfect example in which cumulative var-
iations of each component of this enzymatic cascade could
strongly affect the overall activity of the system.37
An important limitation of our study was the lack of
a more comprehensive genetic analysis of other RAS394 The Journal of Thoracic and Cardiovascular Surgcandidate genes (eg, angiotensinogen and angiotensin II
type I receptor genes) and for which a functional polymor-
phism exists.
Second, given the case–control design, potential con-
founding factors can never be completely excluded in an ob-
servational study. Another limitation of our study was the
nature of the control population, which consisted of volun-
teers or healthy donors.We could not rule out the possibility
that these participants might have had asymptomatic aortic
pathologic features because thoracic aortic imaging was not
conducted. However, we also included a group of patients
with atherosclerosis as another control group to better deter-
mine whether ACE polymorphism is causally related to the
presence of TAA.
In conclusion, our results strongly support that ACE I/D
polymorphism represents a genetic biomarker of increased
susceptibility to TAA, confirming the key role of the RAS
as an underlying cause of aneurysmal aortic disease. These
findings could have a significant effect for both early detec-
tion and effective pharmacologic treatment of aortic disease.
We thank Marco Borbotti e Daniele Ferri for their administra-
tive support.
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